LINC01882: A Potential Drug Target and Biomarker (G100996324)

Target Name: LINC01882

NCBI ID: G100996324

LINC01882

Other Name(s): Long intergenic non-protein coding RNA 1882 | long intergenic non-protein coding RNA 1882

LINC01882: A Potential Drug Target and Biomarker

LINC01882 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is long non-coding RNA-like protein LINC01882, and it is also known as hnRNA-RISC-ERC-HF1. This protein has been shown to play a role in the development and progression of various diseases, including neurodegenerative disorders, cardiomyopathy, and kidney disease. As a result, LINC01882 has become a focus of interest in the scientific community, with researchers studying its potential as a drug target or biomarker.

The LINC01882 gene is located on chromosome 6p21.2 and has a length of 231 amino acid residues. It is a non-coding RNA molecule that is translated into a protein of 21 kDa. The protein has been shown to have various functions, including the regulation of gene expression, DNA replication, and cell survival.

One of the most significant functions of LINC01882 is its role in the development and progression of neurodegenerative disorders. Neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of brain cells and their associated functions. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others.

LINC01882 has been shown to be involved in the development and progression of neurodegenerative disorders by regulating the expression of genes that are involved in neurodegeneration. For example, studies have shown that LINC01882 can interact with the protein heat shock factor (HSF) to regulate the expression of genes involved in neurogenesis and neuronal survival. Additionally, LINC01882 has been shown to play a role in the regulation of the neurotransmitter dopamine, which is involved in the treatment of neurodegenerative disorders.

LINC01882 has also been shown to be involved in the development and progression of cardiomyopathy, a condition in which the heart muscle becomes weakened and less efficient in pumping blood. Cardiomyopathy can be caused by a variety of factors, including genetic, metabolic, and physical exertion.

LINC01882 has been shown to be involved in the development and progression of cardiomyopathy by regulating the expression of genes involved in cardiac function and fibrosis. For example, studies have shown that LINC01882 can interact with the protein transforming growth factor-beta (TGF-beta) to regulate the expression of genes involved in cardiac fibrosis. Additionally, LINC01882 has been shown to play a role in the regulation of the myocardial contractility, which is a critical factor in cardiac function.

LINC01882 has also been shown to be involved in the development and progression of kidney disease, a condition in which the kidneys become less efficient in removing waste products from the blood. Kidney disease can be caused by a variety of factors, including genetic, metabolic, and environmental factors.

LINC01882 has been shown to be involved in the development and progression of kidney disease by regulating the expression of genes involved in renal function and fibrosis. For example, studies have shown that LINC01882 can interact with the protein Wilms' tumor 1 (WT1) to regulate the expression of genes involved in renal fibrosis. Additionally, LINC01882 has been shown to play a role in the regulation of the blood pressure, which is a critical factor in renal function.

In conclusion, LINC01882 is a protein that has been shown to play a

Protein Name: Long Intergenic Non-protein Coding RNA 1882

The "LINC01882 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01882 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets